Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...

The right-wing argues, as Project 2025 puts it, that government negotiations on Medicare drugs amount to “price controls” that will reduce patient access to new medication. That’s news to the citizens ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Coverage of obesity drugs in health plans and the rapid adoption of artificial intelligence are two areas of change that health plans will face during the coming year. A panel of Avalere experts ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.